Abstract
Review of the evidence for current ambulatory heart failure treatment regimens in adults and their applicability in pediatric heart failure. There is promising recent research in treatment with phosphodiesterase-5 inhibitors in single ventricle patients with heart failure, including possible benefits to reduce symptoms and improve exercise tolerance. Therapies for adults cannot be assumed to be generally applicable to all pediatric heart failure patients, especially in patients with systemic right ventricles or single ventricle physiology. Contrary to adult heart failure regimens, evidence supports treatment of symptomatic, but not asymptomatic, heart failure with angiotensin-converting enzyme inhibitors and beta-blockers in certain pediatric patients. Implantable cardioverter defibrillators continue to be used sparingly in children compared with adults due to low risk of sudden cardiac death. Finally, cardiac resynchronization therapy may be beneficial in children with symptomatic heart failure and moderate to severe dysfunction, although applying adult criteria to children remains a challenge.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
